The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-01-26
DOI
10.1093/jnci/djz011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: A systematic review
- (2018) Federica Duregon et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain
- (2018) Katherine Stockstill et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Trial designs for chemotherapy-induced peripheral neuropathy prevention
- (2018) Jennifer S. Gewandter et al. NEUROLOGY
- Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics
- (2017) Andreas A. Argyriou et al. Nature Reviews Neurology
- Chemotherapy-induced peripheral neuropathy clinical trials
- (2017) Jennifer S. Gewandter et al. NEUROLOGY
- Paclitaxel Reduces Axonal Bclw to Initiate IP 3 R1-Dependent Axon Degeneration
- (2017) Sarah E. Pease-Raissi et al. NEURON
- Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial
- (2017) Philipp Zimmer et al. SUPPORTIVE CARE IN CANCER
- Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
- (2017) Ian R. Kleckner et al. SUPPORTIVE CARE IN CANCER
- A Systematic Review of Treatment of Painful Diabetic Neuropathy by Pain Phenotype versus Treatment Based on Medical Comorbidities
- (2017) Luiz Clemente Rolim et al. Frontiers in Neurology
- Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
- (2016) D. L. Hertz et al. CLINICAL CANCER RESEARCH
- The emerging role of FTY720 (Fingolimod) in cancer treatment
- (2016) Christopher White et al. Oncotarget
- Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity
- (2016) Jing Zhu et al. Scientific Reports
- Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)
- (2015) Deirdre R. Pachman et al. JOURNAL OF CLINICAL ONCOLOGY
- National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons
- (2015) Neil Majithia et al. SUPPORTIVE CARE IN CANCER
- The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer
- (2015) N C Hait et al. Oncogenesis
- Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy
- (2014) F. Streckmann et al. ANNALS OF ONCOLOGY
- Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy
- (2014) K S Courneya et al. BRITISH JOURNAL OF CANCER
- The Development and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the Sphingosine 1-Phosphate Receptor Subtype 1
- (2014) Kali Janes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
- (2014) Marta Seretny et al. PAIN
- The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study
- (2014) Dyveke T. Demant et al. PAIN
- Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation
- (2013) Jing Zhu et al. ANNALS OF NEUROLOGY
- Second generation S1P pathway modulators: Research strategies and clinical developments
- (2013) Marc Bigaud et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production
- (2013) Lei Gong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain
- (2013) Daniela Salvemini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)
- (2013) Yaqin Han et al. Frontiers in Pharmacology
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms
- (2012) Christian A. von Hehn et al. NEURON
- Reliability and Validity of Gait Analysis by Android-Based Smartphone
- (2012) Shu Nishiguchi et al. Telemedicine and e-Health
- The BCL-2 Family Reunion
- (2010) Jerry E. Chipuk et al. MOLECULAR CELL
- BCL-2 family antagonists for cancer therapy
- (2008) Guillaume Lessene et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started